welcome
HGSI Human Genome: Cowen Healthcare Conference Summary (32.75 +0.94)
During the call, the co said that Benlysta had no significant safety
signals and it has been a very well tolerated drug so far. HGSI said that there
has been no pricing decision yet. The co targets US and EU submissions in 2Q10.
Mgmt said that 150 sales representatives will be enough between two companies.
Co is focused on trying to stay ahead of demand of product. HGSI has
state-of-the-art process development and manufacturing capability. Mgmt is
currently pursuing capacity expansion strategies to meet peak demand. Co said
that the potential for market growth is explosive. Co noted that this year it
expects a heavier cash burn than previous years, in the $300-350 mln range.
signals and it has been a very well tolerated drug so far. HGSI said that there
has been no pricing decision yet. The co targets US and EU submissions in 2Q10.
Mgmt said that 150 sales representatives will be enough between two companies.
Co is focused on trying to stay ahead of demand of product. HGSI has
state-of-the-art process development and manufacturing capability. Mgmt is
currently pursuing capacity expansion strategies to meet peak demand. Co said
that the potential for market growth is explosive. Co noted that this year it
expects a heavier cash burn than previous years, in the $300-350 mln range.
Comment
© 2010 Created by Roger Carter.
You need to be a member of traddr! to add comments!
Join traddr!